• Description
  • Programmes
  • Contact

Sectors: Health, Innovation, New technologies, Research, Services

Beneficiaries: Administrations States, Corporations, Non-profit organisations, Research centres, SMEs, Universities

Regions: Candidate countries, European Economic Area, European Union, Mediterranean countries, Northern America

Category: Call for proposals

Additional info regions:

Countries participating to the call for proposals: Austria, Belgium, Canada, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Romania, Spain, Sweden, Turkey

Amount:

To view this information, please connect.

Linkedin:

WE Funding – ERA PerMed – Support…
Funds for: Supporting transnational research projects in the field of personalised medicine
Main beneficiaries: Universities, Companies

Responsible: European Commission

Useful:

To view this information, please connect.

Contact:

To view this information, please connect.

Amorce:

Funds for: Supporting transnational research projects in the field of personalised medicine
Main beneficiaries: Universities, Companies

Priorities and funded actions:

Objectives
* Foster research and innovation activities that build close linkages between basic biomedical research, clinical research, physical sciences and bioengineering, bioinformatics and biostatistics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications across the participating countries and beyond;
* Improve disease management, based on broader and more efficiently elaborated patient stratification, diagnostics and tailored treatment protocols, and disease prevention. This includes early involvement of regulatory authorities as well as close interaction with the different key players along the value chain to bridge the gap between first discoveries or inventions until market access

Priorities
* Support translational research projects in the field of Personalised Medicine;
* Encourage and enable interdisciplinary collaborations towards implementation of PM, combining pre-clinical and/or clinical research with bio-informatics components and research on relevant ethical, legal and social aspects and/or research on the optimisation of health care systems;
* Encourage collaboration between academia, clinical/public health research, private partners (e.g. SMEs) as well as policy-makers, regulatory/HTA agencies and patient organisations

Among financed actions
* Module 1A – Pre-clinical research:
– Development and implementation of high-throughput pre-clinical models for validation of data and hypotheses from human population, clinical and molecular studies and/or prediction of clinical outcome;
– Classification of diseases at the molecular level, which can be instrumental for successful implementation of PM, including pre-clinical studies for validation of biomarkers that can be used in diagnosis, prognosis and prediction of response to treatment;
– Validation (in preclinical models, in terms of reproducibility, safety and efficiency) and characterisation of the role of biomarkers in predictive medicine for future prevention, assessment and management of diseases
* Module 1B – Clinical research:
– Improvement, validation and combination of different tools (e.g. imaging) as well as omic tools for diagnostics and different integrated analytical methods;
– Development and evaluation of concepts for innovative clinical trial methodologies, suitable for PM approaches;
– Development of new concepts and stratification strategies in exploratory clinical studies
* Module 2A – Data and ICT, Enabling technology:
– Research on data harmonisation strategies and development of specific ICT solutions for research questions addressed in the consortium;
– Strategies for developing common quality standards, semantics and minimal indicators, and metrics for data and metadata;
– Development of new devices/tools for data collection
* Module 2B – Data and ICT, Towards application in Health care:
– Research on data integration and interpretation of complex/multifactorial diseases and other diseases, aimed to advance PM;
– Development of innovative and easy-to-handle clinical decision support tools tailored to health care professionals to provide suitable and consequent interpretation of complex multifactorial and multimodal data;
– Development of telehealth and telemedicine applications to support the implementation of PM
* Module 3A – Optimising Health Care systems:
– Research on the analysis, comparison and optimisation of national and regional health care systems in the context of PM;
– Research on development, application and adaptation of new models and approaches for health care and their application/adaptation to healthcare systems in different regions/countries;
– Research on the overall economic impact of an optimised health care system based on improved treatment of diseases and prevention within the framework of PM
* Module 3B – Ethical, legal and social aspects:
– Research on optimised data security, protection, confidentiality, privacy and ownership within PM approaches;
– Research on adequate regulatory structures and pathways in PM;
– Research on ethical, legal and social aspects in the context of decision support systems, especially with the use of artificial intelligence

Additional information
* This call for proposals is a restricted call for proposals. In first instance, only concept notes will be evaluated

* Initial duration of the action: 36 months

* Eligibility
– Be a legal person;
– Be a public or private entity;
– Be: an academic (Universities, HEIs) or research institute; an organisation from the clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations); or a private partner (companies, including SMEs);

– A consortium composed of at least 3 partners eligible for funding, independent from each other and coming from three different countries whose funders participate in the call, must be established. No more than two partners established in the same country are allowed;

– Partners not eligible for funding by one of the organisations participating in this JTC may participate in projects if they are able to secure their own funding. No more than one partner with its own funding is allowed in consortia with at least 3 partners eligible for funding;

– The maximum number of partners in a consortium is 6. However, a consortium can be composed of a maximum of 7 partners if one of these partners is established in an underrepresented country;

– Each project proposal must address at least one module of Research area 3 (Research towards responsible implementation in Health Care) and at least one module or Research area 1 (Translating basic to clinical research and beyond) or 2 (Integrating Big Data and ICT solutions)